Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cell therapy for tough blood cancers put on hold

NCT ID NCT05336409

Disease control Sponsor: Century Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Jan 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). 2. Must have met the following criteria for prior treatment: 1. Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor \[CAR\] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator. 2. Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator. 3. Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies. 3. Measurable disease on screening evaluations. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Adequate organ function. 6. Life expectancy of ≥12 weeks. Exclusion Criteria: 1. Any condition that confounds the ability to interpret data from the study. 2. Central nervous system (CNS)-only involvement by malignancy. (Note: participants with secondary CNS involvement are allowed.) 3. Prior allogeneic stem cell transplant. 4. Presence of clinically significant CNS pathology. 5. Other comorbid conditions defined in the protocol. 6. Use of prohibited medications within the washout period defined in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aggressive non-Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma indolent B-cell non-Hodgkin lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aggressive non-Hodgkin lymphoma Indolent non-Hodgkin lymphoma R/R CD19-positive B-cell malignancies

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Corewell Health

    Grand Rapids, Michigan, 49503, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Houston Methodist Research Institute

    Houston, Texas, 77030, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Oncology Hematology Care, Inc-Kenwood

    Cincinnati, Ohio, 45236, United States

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • UT Southwestern

    Dallas, Texas, 75390, United States

  • University of California San Diego, Moores Cancer Center

    San Diego, California, 92093, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45229, United States

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201, United States

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.